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Abstract
Objective: Individuals with the neurofibromatosis type 2 (NF2) cancer predisposition syndrome develop spinal cord glial
tumors (ependymomas) that likely originate from neural progenitor cells. Whereas many spinal ependymomas exhibit
indolent behavior, the only treatment option for clinically symptomatic tumors is surgery. In this regard, medical therapies
are unfortunately lacking due to an incomplete understanding of the critical growth control pathways that govern the
function of spinal cord (SC) neural progenitor cells (NPCs).
Methods: To identify potential therapeutic targets for these tumors, we leveraged primary mouse Nf2-deficient spinal cord
neural progenitor cells.
Results: We demonstrate that the Nf2 protein, merlin, negatively regulates spinal neural progenitor cell survival and glial
differentiation in an ErbB2-dependent manner, and that NF2-associated spinal ependymomas exhibit increased ErbB2
activation. Moreover, we show that Nf2-deficient SC NPC ErbB2 activation results from Rac1-mediated ErbB2 retention at the
plasma membrane.
Significance: Collectively, these findings establish ErbB2 as a potential rational therapeutic target for NF2-associated spinal
ependymoma.
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Introduction
Spinal cord (SC) ependymomas are well-delineated gliomas
characterized by prominent glial fibrillary acidic protein (GFAP)
expression [1]. Converging genomic and cell biology evidence
supports a radial glial/neural progenitor cell of origin for these
tumors [2,3]. As such, increasing neural progenitor cell (NPC)
marker (nestin) expression has been associated with worse clinical
outcome in patients with ependymoma [4]. Although ependymo-
mas from different regions of the central nervous system (CNS) are
histologically similar, they are clinically [5] and genetically [3,6]
distinct, suggesting that they represent a collection of different
diseases with unique genetic drivers and responses to therapy.
Currently, there are limited therapeutic options for ependymomas
arising in the spinal cord, underscoring the need to identify the key
molecular changes that specifically drive SC ependymoma growth
in order to design treatments that target the signaling pathways de-
regulated in these tumors.
Potential insights into the molecular pathogenesis of ependy-
moma are likely to derive from studies focused on familial
syndromes in which affected individuals are prone to these tumors.
One such syndrome, neurofibromatosis type 2 (NF2) is an
autosomal dominant inherited cancer predisposition syndrome,
caused by a germline mutation in the NF2 tumor suppressor gene:
35–53% of individuals with NF2 develop ependymoma [7], with a
striking predilection for the cervical or thoracic spinal cord (62–
86% of tumors) [8]. The importance of the NF2 gene to
ependymoma pathogenesis is further emphasized by the observa-
tion that NF2 gene mutation and loss of merlin expression is found
in one-third of sporadic (non-syndromal) ependymomas [9–11].
Moreover, the majority of ependymomas exhibiting NF2 loss
occur in the spinal cord [12]. For these reasons, NF2 represents a
tractable genetic model system to identify potential therapeutic
targets for spinal ependymoma.
In the current study, we leveraged complementary genetic and
pharmacologic approaches to demonstrate that merlin functions as
a critical negative regulator of SC NPC survival and glial
differentiation. Moreover, merlin controls NPC homeostasis by
selectively suppressing ErbB2 activation, supported by the fact that
both Nf2-deficient mouse SC NPCs and human NF2-patient
spinal ependymomas exhibit increased ErbB2 activity. We further
show that ErbB2 activation in Nf2-deficient SC NPCs requires
Rac1 to retain ErbB2 in an active form at the plasma membrane.
Because blockage of ErbB2 function reverses the enhanced
survival and gliogenesis in Nf2-deficient SC NPCs, these studies
establish ErbB2 as a potential rational therapeutic target for spinal
ependymoma.
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Figure 1. Merlin loss increases SC NPC growth, glial differentiation and cell survival. Nf2 loss results in a (A) 1.8-fold increase in
neurosphere diameter (p,0.0001; two-tailed Mann-Whitney U-test), (B) 3.6-fold increase in cell number at day 8 (p,0.001; 2-way ANOVA), and (C) a
1.7-fold increase in clonogenic expansion relative to WT SC NPCs (p = 0.003; two-tailed; two-tailed Mann-Whitney U-test). (D, E) Nf2 loss results in a 2-
fold decrease in cell death, as assessed by cleaved caspase-3 and TUNEL (p = 0.0008 and p= 0.0442; two-tailed Mann-Whitney U-test). (F) Nf2 loss has
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Materials and Methods
Ethics Statement
All mice were maintained in strict accordance with recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health and active animal studies
protocols approved by the Animal Studies Committee at the
Washington University School of Medicine (Protocol#20110111).
All surgery was performed under isoflurane anesthesia, and all
efforts were made to minimize suffering. All efforts were made to
optimize experiments and reduce the number of animals used.
Human spinal cord and ependymoma sections were obtained
from St. Jude Children’s Research Hospital (Memphis TN) and
the Washington University School of Medicine Tissue Procure-
ment Core (http://pathology.wustl.edu/research/cores/ltp/
request.php), and used under an Institutional Review Board
approved Human Studies Protocol (#201103323) to comply with
ethical standards as well as government and institutional
regulations. No direct patient consent was necessary, as these
specimens were de-identified.
Mice
Nf2flox/flox mice carrying a LoxP insertion in the Nf2 gene [13]
were maintained at the Washington University School of
Medicine. Male and female embryos (E12.5) from mice main-
tained on a mixed C57BL/6 and FVB/N background were used
for all experiments.
Culture and Generation of Nf22/2 Neurospheres
Spinal cords dissected from E12.5 mouse Nf2flox/flox embryos
were used to generate NPCs as previously reported [14]. Briefly,
spinal cords were removed from embryonic day 12.5 (E12.5)
decidua of timed-pregnant females and processed to obtain single-
cell suspension of neural progenitors (neurospheres). Dissected
spinal cords were digested with trypsin digest buffer containing
0.2% BSA (Sigma, St. Louis, MO), 0.5 mg/ml DNase I (Sigma),
and 10% trypsin-EDTA stock (BioWhittaker, Walkersville, MD) in
HBSS at 37uC for 15 min in a volume of 0.7 ml per litter. Equal
volumes of 10% FBS medium containing 10% FBS (Life
Technologies, Gaithersburg, MD) and low glucose DMEM/
(Sigma) were added, and spinal cords were triturated with fire-
polished Pasteur pipettes. Pelleted cells were washed with
dissociation medium containing 15 mM HEPES (Sigma), 0.5%
glucose in HBSS. Cells were finally resuspended in NSC medium
containing a 5:3 mixture of DMEM low glucose: Neurobasal
medium (Life Technologies), 0.5 mM 2-mercaptoethanol, 2 mM
L-glutamine, 5 IU of penicillin, and 5 mg/ml streptomycin
(BioWhittaker) supplemented with 1% N2 supplement (Life
Technologies), 2% B27 supplement (Life Technologies), 20 ng/
ml epidermal growth factor (EGF) (Sigma), and 20 ng/ml basic
fibroblast growth factor (FGF) (R & D Systems, Minneapolis, MN).
Following infection with adenovirus containing either LacZ (wild-
type (WT) NPCs) or Cre (Nf22/2 NPCs), merlin expression was
determined by Western blotting (6 days after adenovirus infection).
NPC Assays
Neurospheres were trypsinized (as described above) and plated
into individual wells of ultralow-binding 24-well plates with
complete NPC medium containing EGF and FGF. For assays in
which the diameter and average number of neurospheres were
measured, single neurospheres from WT and Nf22/2 NPCs were
selected, trypsinized and individually plated into a single well of a
24-well plate. After 6 days, the size (diameter/cell growth) and
number (clonogenic expansion) of the resulting secondary neuro-
spheres was determined using Metamorph analysis software
(Molecular Devices, Sunnyvale CA). Six wells per group per
experiment were counted for these studies. For the proliferation
assays, neurospheres from each group were trypsinized, 104 cells
were seeded in triplicate, and the number of cells assessed by direct
cell counting (at 4, 6, and 8 days). Three wells per group per
experiment were counted for these studies. Apoptosis was
determined by counting the percent of cleaved caspase-3+ cells
(1:500 dilution; Cell Signaling Technology, Beverly MA) or
Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick
end labeling (TUNEL; Roche, Indianapolis IN)-immunoreactive
cells relative to the total number of DAPI (49, 69-diamidino-2-
phenylindole)-positive cells. Pharmacologic inhibitor experiments
used 104 cells per well (NSC23766, 10 mM; AG825, 10 mM;
Sigma, St. Louis MO) for 6 days. All experiments were repeated at
least three times with similar results.
Viral Transduction
Murine stem cell virus (MSCV) infection was employed to
express human WT or mutant (L64P patient mutation) merlin,
mutant ErbB2 (V659E; Martine Roussel, St. Jude Children’s
Research Hospital, Memphis TN), or dominant-negative Rac1
(Rac1N17) as previously described [15]. Mouse Erbb2 (GenBank
accession numbers NM_001003817.1 and XM_109715.3-689)
small hairpin RNAs (shRNAs) lentiviral plasmids were obtained
from theWashington University Genome Institute and generated as
previously reported [16]. PLKO virus was used as an empty vector
control. Viruses used are listed in Table S1. Neurospheres were
trypsinized and plated with complete NSC media (as described
above) in ultralow-attachment 100 mm dishes (Corning, NY) and
virus was added (MOI-10) at 37uC overnight. Cells were then
pelleted, plated in fresh complete NSC media and allowed to grow
for 6 days. Neurospheres were then trypsinized and infected with
adenovirus (as described above), and allowed to grow for 6 days.
Cells were then trypsinized and assays were established accordingly.
Western Blotting
Western blots were performed as previously described [17].
Briefly, neurospheres (after 6 days in culture) were lysed in MAPK
lysis buffer (20 mM Tris (pH 7.0), 10 mM EGTA, 400 mM B-
glycerophosphate, 1% NP-40, 2.5 mM MgCl2, and 2 mM sodium
orthovanadate with protease inhibitors (leupeptin, aprotinin, and
phenylmethylsulfonyl fluoride). For all experiments, 30 mg of
protein per sample were loaded in each lane. Proteins were
separated by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to polyvinylidene difluoride membranes
(Millipore, Billerica, MA) prior to detection with phospho-specific
antibodies. Antibodies that detect the total expression of the
corresponding signaling intermediate as well as a-tubulin were
used as controls for equal protein loading and quantitation. Active
Rac1 (Rac1-GTP) was determined by PAK1-PBD affinity
chromatography (Rac1 activation Assay Kit, Millipore, Bedford
no effect on the activation (cleavage) of caspase-6, -9, or -12 or PARP (statistics reported in Supplementary Figure 1C–F). (G) Nf2 loss results in
increased glial (3-fold) (p = 0.0002; two-tailed Mann-Whitney U-test), but decreased neuronal (4.6-fold) (p,0.0001; two-tailed Mann-Whitney U-test)
and oligodendrocyte (5-fold) differentiation (p,0.0001; two-tailed Mann-Whitney U-test). The data were normalized to the field of view. Values
denote the mean 6 SEM. (*) p,0.05; (**) p,0.001; (***) p,0.0001.
doi:10.1371/journal.pone.0097320.g001
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Figure 2. Wild-type, but not mutant, merlin re-expression restores SC NPC properties to WT levels. (A) Re-expression of WT (MSCV.NF2),
but not mutant (MSCV.NF2.L64P), merlin reduced (B) SC NPC growth (diameter) and clonogenic expansion (neurospheres) to WT levels (diameters:
MSCV, p,0.001; L64P, p,0.001; hNf2, p = 0.1584; average number of neurospheres: MSCV, p,0.0421; L64P, p,0.05; hNf2, p = 0.7138; two-way
ANOVA with Bonferroni post-test). (C) Wild-type (WT; MSCV.NF2), but not mutant (MSCV.NF2.L64P), merlin expression in Nf22/2 SC NPCs decreases
cell number at day 8 (MSCV, p,0.001; L64P, p,0.05; hNf2, p = 0.200; two-way ANOVA with Bonferroni post-test) and (D) glial differentiation to WT
levels (MSCV, p,0.001; L64P, p,0.001; hNf2, p = 0.7238; two-way ANOVA with Bonferroni post-test). Wild-type (WT; MSCV.NF2), but not mutant
(MSCV.NF2.L64P), merlin expression in Nf22/2 NPCs increases (E) neuronal (MSCV, p,0.001; L64P, p,0.001; hNf2- p = 0.1797; two-way ANOVA with
Bonferroni post-test) and (F) oligodendrocyte differentiation to WT levels (MSCV, p,0.01; L64P, p,0.01; hNf2, p = 0.7308; two-way ANOVA with
Bonferroni post-test. The data were normalized to the field of view. Values denote the mean 6 SEM. (*) p,0.05; (**) p,0.001; (***) p,0.0001.
doi:10.1371/journal.pone.0097320.g002
Nf2 Controls Spinal Neural Stem Cell Homeostasis
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MA) according to the manufacturer’s recommendations. Appro-
priate HRP-conjugated secondary antibodies (Cell Signaling,
Beverly MA) were used for detection by enhanced chemilumines-
cence (New England Biolabs, Beverly MA). Antibodies used are
listed in Table S2.
Subcellular Fractionation
Subcellular fractionation was performed as previously described
[18]. Briefly, following hypotonic (10 mM HEPES at pH 7.9,
1.5 mM MgCl2, 10 mM KCl, protease inhibitors) lysis, nuclei
were pelleted by centrifugation, and supernatants were subjected
Figure 3. Merlin loss leads to increased ErbB2 activation. (A) Nf2 loss does not change the activation status of AKT (S473), FAK (Y576/577),
mTOR (S2448), ERK1/2 (Thr202/Y204), SRC (Y416), or YAP (S127). The quantification of all independent experiments is shown in Fig. S2A–I. (B) Nf2 loss
results in a 2-fold increase in ErbB2 hyperactivation initially demonstrated with a commercial activated RTK array (left panel) and subsequently
confirmed using independent samples and a phospho-specific ErbB2 antibody (Tyr877 phosphorylation; bottom and right panel) (p = 0.0145; two-
tailed Mann-Whitney U-test). (C) Nf2 loss does not increase the phosphorylation (activation) status of EGFR (Tyr1068), ErbB2 (Tyr1221/1222), ErbB3
(Tyr1222), or ErbB4 (Tyr1284). The quantification of all independent experiments is shown in Fig. S2J–M. (D) Normal human spinal cords lack ErbB2
activation, whereas (E) robust pErbB2 immunoreactivity was observed in two representative NF2-patient ependymomas. Values denote the mean 6
SEM. (*) p,0.05; (**) p,0.001; (***) p,0.0001.
doi:10.1371/journal.pone.0097320.g003
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to ultracentrifugation at 100,0006g for 1 h at 4uC to generate
cytosolic and membrane fractions. Equal percentages of each
fraction (10 ml per lane (200 ml of total volume)) were subjected to
SDS-PAGE and immunoblot analysis.
Immunohistochemistry and Immunocytochemistry
Sections were treated with citrate antigen retrieval solution
(10 mM, pH 6.0) and stained with pErbB2 (1:50 dilution) as
previously described [14]. Images were acquired on a Nikon
Eclipse E600 microscope (Nikon Corporation, Tokyo, Japan)
equipped with a Leica EC3 optical camera and Leica Application
Figure 4. Increased Nf2-deficient SC NPC growth and glial differentiation is reversed by pharmacologic ErbB2 inhibition. (A)
Pharmacologic ErbB2 inhibition (AG825; 10 mM) reduces Nf22/2 SC NPC neurosphere diameters (Vehicle: WT vs. Nf22/2, p,0.001; AG825: WT vs.
Nf22/2, p = 0.2308; two-way ANOVA with Bonferroni post-test) and (B) increases cell death (% cleaved caspase-3+ cells) to WT levels (Vehicle: WT vs
Nf22/2, p,0.001; AG825: WT vs. Nf22/2, p = 0.1903; two-way ANOVA with Bonferroni post-test). (C) Pharmacologic ErbB2 inhibition (AG825; 10 mM)
reduces Nf22/2 SC NPC glial differentiation to WT levels (Vehicle: WT vs. Nf22/2, p,0.001; AG825: WT vs. Nf22/2, p = 0.8633; two-way ANOVA with
Bonferroni post-test). The data were normalized to the field of view. Values denote the mean 6 SEM. (*) p,0.05; (**) p,0.001; (***) p,0.0001.
doi:10.1371/journal.pone.0097320.g004
Nf2 Controls Spinal Neural Stem Cell Homeostasis
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Suite 2.10 (Leica Microsystems, Wetzlar, Germany). Immunocy-
tochemistry was performed on trypsinized NPCs grown in 50 mg/
mL poly-D-lysine-coated and 10 mg/mL fibronectin-coated 24-
well plates containing defined medium (5:3 mixture of DMEM low
glucose (Life Technologies): neurobasal medium (Life Technolo-
gies), 0.5 mM 2-mercaptoethanol, 2 mM L-glutamine, 5 IU
penicillin, and 5 mg/ml streptomycin (Life Technologies) supple-
mented with 1% N2 supplement (Life Technologies) and 2% B27
supplement (Life Technologies)) without growth factors. After 5
days in culture, cells were fixed and stained with appropriate
primary antibodies at 4uC overnight. For fluorescence detection,
Alexa Fluor-tagged secondary antibodies (Molecular Probes,
Eugene OR) were used and cells were counterstained with DAPI.
Statistical Analysis
Statistical significance (p,0.05) was determined using the
appropriate test as described in figure legends using GraphPad
Prism 5.0 software (GraphPad Inc., La Jolla CA).
Results and Discussion
Merlin Negatively Regulates SC NPC Growth and Glial
Differentiation
Since spinal cord ependymomas are hypothesized to originate
from radial glial-like stem/progenitor cells [2,3] expressing the
fatty acid binding protein-7 (brain lipid binding protein, BLBP)
(Fig. S1A), initial studies employed genetically-engineered mice in
which the NF2 gene was conditionally deleted in BLBP+ cells
(Nf2BLBPCKO mice) using a previously published BLBP-Cre strain
[19]. However, no viable Nf2BLBPCKO pups were born, likely due
to a requirement for merlin expression in BLBP+ cells during mid-
embryonic development (E9.5) [19]. For this reason, we chose to
employ primary embryonic spinal cord (SC) NPC cultures from
Nf2 floxed mice (Nf2flox/flox; [13]) in which merlin expression could
be eliminated following adenoviral delivery of Cre recombinase
(Ad5Cre). Consistent with an essential role for merlin in SC NPC
homeostasis, Nf2 inactivation results in increased NPC growth
(1.8-fold increase in neurosphere diameter, Fig. 1A; 3.6-fold
increase in cell number at day 8, Fig. 1B) and a 1.7-fold increase in
clonogenic expansion (secondary neurosphere formation) (Fig. 1C).
To define the cellular mechanism responsible for merlin regulation
of NPC growth, we initially measured programmed cell death.
Following Nf2 inactivation, there was a 2-fold decrease in
apoptosis as measured by cleaved caspase-3 immunocytochemistry
and Western blotting (Fig. 1D and E) as well as by TUNEL
staining (Fig. 1D). No changes in the activity (cleavage) of other
caspase family members were observed in Nf2-deficient SC NPCs
(Fig. 1F and Fig. S1B–F).
Since ependymomas are glial cell tumors, we next sought to
determine whether Nf2 loss in NPCs increases gliogenesis.
Following in vitro differentiation, merlin loss results in a 3-fold
increase in glial differentiation relative to Ad5LacZ-infected (wild-
type; WT) SC NPCs. Following merlin loss, there is also a decrease
in neuronal (4.7-fold decrease) and oligodendroglial (5-fold
decrease) differentiation (Fig. 1G).
To establish a causal relationship between merlin loss and SC
NPC function, merlin was re-expressed in Nf2-deficient NPCs by
retroviral infection (Fig. 2A). In these experiments, expression of
WT, but not NF2-patient mutant (L64P; [20,21]), merlin restored
SC NPC neurosphere diameters (Fig. 2B), clonogenic expansion
(Fig. 2B), cell number (Fig. 2C), and multi-lineage differentiation
(Fig. D–F) to WT levels. Collectively, these results demonstrate
that merlin is a direct regulator of SC NPC growth and glial
differentiation in vitro.
Figure 5. Increased Nf2-deficient SC NPC growth and glial differentiation is reversed by genetic ErbB2 silencing. (A) shRNA-mediated
ErbB2 silencing (B) decreases Nf22/2 SC NPC neurosphere diameters (PLKO: WT vs. Nf22/2, p,0.001; shRNA: WT vs. Nf22/2, p = 0.3821; two-way
ANOVA with Bonferroni post-test) (C) and glial differentiation to WT levels (PLKO: WT vs. Nf22/2, p,0.001. shRNA: WT vs. Nf22/2, p = 0.3704; two-
way ANOVA with Bonferroni post-test). The data were normalized to the field of view. Values denote the mean6 SEM. (*) p,0.05; (**) p,0.001; (***)
p,0.0001.
doi:10.1371/journal.pone.0097320.g005
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Merlin Negatively Controls ErbB2 Activation
To define the mechanism underlying merlin regulation of NPC
homeostasis, we examined the activation status of signaling
pathways previously shown to govern Nf2-deficient cell growth,
including AKT, FAK, mTOR, YAP, and SRC [17,22–24].
However, none of these signaling intermediates/pathways were
hyperactivated following Nf2 loss in SC NPCs (Fig. 3A and Fig.
S2A–I). Next, we sought to determine whether merlin growth
regulation involves suppression of receptor tyrosine kinase (RTK)
activation, based on previous studies in differentiated forebrain
astrocytes [17] and other non-nervous system cell types [25].
Using a commercial activated RTK array, the only RTK in Nf2-
deficient SC NPCs with significant activation over their WT
counterparts was ErbB2 (Fig. 3B, top left panel). We confirmed
this result using independent Nf22/2 SC NPC cultures, and
found a 2-fold increase in ErbB2 activation relative to WT SC
NPCs using Y877 phospho-specific antibodies (Fig. 3B, bottom
and right panel). Hyperactivation of other ErbB family members
(EGFR, ErbB3, ErbB4) using phospho-specific antibodies was not
observed (Fig. 3C and Fig. S2J–M).
Since over 75% of pediatric ependymomas express ErbB2 [26]
and increased ErbB family receptor tyrosine kinase signaling has
been reported in the hallmark NF2-associated tumor (vestibular
schwannoma) [27,28] we examined ErbB2 activation in normal
human spinal cord and in two representative spinal ependymomas
from individuals with a confirmed diagnosis of NF2. These tumors
are not typically removed, thus limiting a more exhaustive
analysis. While normal spinal cord autopsy specimens from
individuals ranging from 2 weeks to 14 years of age lacked ErbB2
activation (Fig. 3D), the two human NF2-patient ependymoma
samples exhibited robust phospho-ErbB2 expression (Fig. 3E).
Figure 6. Expression of an activated ErbB2 molecule mimics Nf2 loss in SC NPCs. (A) Constitutively-activated ErbB2 (V659E) expression
increases SC NPC neurosphere diameters (1.4-fold) (p = 0.0021; two-tailed Mann-Whitney U-test), (B) decreases NPC apoptosis (% cleaved caspase-3+
cells; 2.6-fold) (p,0.0001; two-tailed Mann-Whitney U-test), and (C) increases glial differentiation (2.6-fold) (p = 0.0006; two-tailed Mann-Whitney U-
test). The data were normalized to the field of view. Values denote the mean 6 SEM. (*) p,0.05; (**) p,0.001; (***) p,0.0001.
doi:10.1371/journal.pone.0097320.g006
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Figure 7. Merlin negatively regulates SC NPC growth and glial differentiation in a Rac1- and ErbB2-dependent manner. (A) Nf2 loss
results in a 2.6-fold increase in Rac1 activity (statistical analysis shown in Supplementary Figure 2O). (B) Pharmacologic Rac1inhibition decreases
Nf22/2 SC NPC neurosphere diameters (Vehicle: WT vs. Nf22/2 = , p,0.001; NSC23766: WT vs. Nf22/2, p = 0.9540; two-way ANOVA with
Bonferroni post-test) (C) and glial differentiation to WT levels. (Vehicle: WT vs. Nf22/2, p,0.001; NSC23766: WT vs. Nf22/2, p = 0.1738; two-way
ANOVA with Bonferroni post-test). (D) Pharmacologic Rac1 inhibition decreases Nf22/2 SC NPC ErbB2 hyperactivation. (E) Genetic Rac1 inhibition
(Rac1N17 expression) reduces Nf22/2 NPC neurosphere diameters to WT levels. (MSCV: WT vs. Nf22/2, p,0.001; Rac1N17: WT vs. Nf22/2, p = 0.0263;
two-way ANOVA with Bonferroni post-test). (F) Nf22/2 SC NPCs exhibit a 5.4-fold enrichment of ErbB2 in the plasma membrane fraction (p = 0.0265;
two tailed Mann-Whitney U-test). Rac1 inhibition (NSC23766) decreased plasma membrane ErbB2 expression to WT levels. (G) Nf22/2 SC NPCs have
a 2.7-fold increase in ErbB2 enrichment in the membrane fraction when normalized to total ErbB2 levels in the total cell lysates (2.0-fold increase) (p,
0.05; two-way ANOVA with Bonferroni post-test). The data were normalized to the field of view. Values denote the mean 6 SEM. (*) p,0.05; (**) p,
0.001; (***) p,0.0001.
doi:10.1371/journal.pone.0097320.g007
Nf2 Controls Spinal Neural Stem Cell Homeostasis
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Merlin Regulates SC NPC Growth and Glial Differentiation
in an ErbB2-dependent Manner
To establish an essential role for ErbB2 activation in merlin
regulation of SC NPC function, we employed complementary
pharmacological and genetic approaches. In these studies,
pharmacologic ErbB2 inhibition (tyrphostin; AG825) decreased
Nf22/2 NPC neurosphere diameters (Fig. 4A), cell survival
(Fig. 4B), and glial differentiation (Fig. 4C) to WT levels. Similar
results were also obtained using another pharmacological ErbB2
inhibitor (lapatinib; Fig. S2N). Moreover, shRNAi silencing of
ErbB2 expression using two different Erbb2 shRNA constructs
(Fig. 5A) reduced Nf22/2 SC NPC neurosphere diameters
(Fig. 5B) and glial differentiation (Fig. 5C) to WT levels. While we
favor the hypothesis that merlin regulates SC NPC cell survival
and glial differentiation in an ErbB2-dependent manner, these two
processes do not have to be linked and may involve separate
downstream signaling pathways.
To further support ErbB2 activation as an important regulator
of SC NPC homeostasis, we overexpressed a constitutively-
activated ErbB2 (V659E) molecule by MSCV retroviral infection.
Expression of ErbB2-V659E in WT SC NPCs resulted in a 1.4-
fold increase in cell growth (neurosphere diameter; Fig. 6A), a 2.6-
fold decrease in cell death (Fig. 6B), and a 2.6-fold increase in glial
differentiation (Fig. 6C) relative to vector (MSCV) controls.
Collectively, these results establish that ErbB2 is both necessary
and sufficient for merlin regulation of SC NPC growth and glial
differentiation.
Merlin Controls SC NPC Function by Regulating ErbB2
Plasma Membrane Localization and Signaling in a Rac1-
dependent Manner
Next, we sought to define the mechanism underlying merlin
regulation of ErbB2 activation. Western blot analysis revealed that
both phosphorylated and total ErbB2 protein levels were increased
in Nf2-deficient SC NPCs, suggesting that the observed de-
regulated ErbB2 signaling could result from increased plasma
membrane localization. Previous studies from our laboratory and
others have implicated merlin in cytoskeleton dynamics [29,30]
raising the intriguing possibility that ErbB2 membrane localization
and signaling is controlled by Rac1, a downstream merlin target
important for actin cytoskeleton function [31–34]. Consistent with
this model, Rac1 activation was increased 2.6-fold in Nf22/2 SC
NPCs relative to their WT counterparts (Fig. 7A and Fig. S2O).
Moreover, pharmacologic Rac1 inhibition (NSC23766) decreased
Nf2-deficient NPC neurosphere diameters (Fig. 7B) and glial
differentiation (Fig. 7C) to WT levels. To confirm that Rac1 is the
effector responsible for ErbB2 hyperactivation in Nf22/2 SC
NPCs, we found that pharmacologic Rac1 inhibition decreased
ErbB2 activity (Fig. 7D). Similar results were also obtained using a
dominant-negative Rac1 (Rac1N17) molecule (Fig. 7E).
Previous studies in non-nervous system cell types have shown
that merlin loss increases the internalization of another RTK
(EGFR) [35,36]. To determine whether this mechanism might
underlie merlin regulation of ErbB2 activation in Nf2-deficient SC
NPCs, cell fractionation was performed. In these experiments,
Nf22/2 SC NPCs exhibit a 2.7-fold enrichment of ErbB2 in the
plasma membrane fraction (5.4-fold increase) when normalized to
total ErbB2 levels in the total cell lysates (2.0-fold increase) (Fig. 7F,
G). These results support a model in which ErBb2 localization to
the membrane allows ErbB2 to remain in an active, hyper-
phosphorylated state. To determine whether Rac1 controls ErbB2
plasma membrane enrichment, we demonstrate that Pharmaco-
logic Rac1 inhibition (NSC23766) decreased plasma membrane
ErbB2 expression to WT levels (Fig. 7F). Importantly, b-catenin (a
known regulator of cell-cell adhesion) is not hyperactivated in
Nf22/2 NPCs (Fig. S2P). Collectively, these findings establish
that merlin negatively controls NPC function by regulating ErbB2
plasma membrane localization and signaling in a Rac1-dependent
manner.
Conclusions
Spinal cord ependymomas are non-malignant neoplasms with
limited chemotherapeutic options. Currently, the only effective
treatment for clinically-symptomatic tumors is surgery, which
carries significant potential morbidity. In this report, we leveraged
Nf22/2 SC NPCs as an in vitro model system to define the
growth control mechanism underlying spinal ependymoma
pathogenesis relevant to the implementation of biologically-
targeted treatments for these tumors. The finding that merlin
regulates SC NPC growth in a Rac1- and ErbB2-dependent
manner firmly establishes a central growth control target for NF2-
associated spinal ependymoma, and advocate for further studies
addressing the potential use of ErbB2 inhibitors to treat these CNS
neoplasms.
The importance of ErbB2 in NF2-associated tumors is also
highlighted by recent research showing that lapatinib inhibits
vestibular schwannoma growth [28]. Because ependymomas are
thought to arise from radial glial-like progenitor cells in the spinal
cord3, the important relationship between ErbB2 function and
ependymoma is further underscored by the observation that this
specific RTK is required for the establishment and maintenance of
CNS radial glia [37,38]. In addition, ErbB2 is one of the most
frequently mutated genes in human high-grade glioma [39], such
that ErbB2 activation promotes glioma and ependymoma cell line
growth in vitro [26,40]. Similar to our findings in Nf2-deficient SC
NPCs, ErbB2 increases glioma cell growth by inhibiting apoptosis
[40]. Taken together, our findings demonstrate that ErbB2 is a
critical regulator of Nf2-deficient SC NPC survival and glial
differentiation, and support further evaluation in preclinical and
human clinical trials for NF2-associated and select sporadic
ependymomas.
Supporting Information
Figure S1 Merlin re-expression restores Nf2-deficient
SC NPC growth and differentiation to wild-type levels.
(A) The mouse SC ependymal cell layer is immunopositive for fatty
acid binding protein-7 (brain lipid binding protein, BLBP)
expression. (B) Nf2-deficient SC NPCs have a 2-fold decrease in
apoptosis as measured by cleaved caspase-3 (p = 0.0442; two-tailed
Mann-Whitney U-test). (C–F) No changes in the activity (cleavage)
of other caspase family members were observed in Nf2-deficient
SC NPCs (C. Casp-6 –p= 0.6579; C. Casp-9 –p= 0.6579; C.
Casp-12 –p= 0.7000; C. PARP –p=0.1840; two-tailed Mann-
Whitney U-test). Values denote the mean 6 SEM. (*) p,0.05; (**)
p,0.001; (***) p,0.0001.
(TIF)
Figure S2 (A–I) Nf2 loss does not lead to changes in the
activation status of signaling pathways previously implicated in
Nf2-deficient cell growth regulation, including AKT (S473,
p = 0.8857; Thr308, p = 0.6579), FAK (Y576/577, p = 0.6579),
mTOR (S2448, p = 0.6579; Y2446, p = 0.8251), ERK1/2
(Thr202/Y204, p= 0.3429), SRC (Y416, p = 0.8857), and YAP
(S127, p= 0.6579) (two-tailed Mann-Whitney U-test). (J–M)
Hyperactivation of other ErbB family members using phospho-
specific antibodies was not observed (EGFR Tyr1068, p = 0.6579;
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ErbB2 Y1221–1222, p= 0.4; ErbB3 Tyr1222, p = 1.000; and
ErbB4 Tyr1284, p = 0.9162) (two-tailed Mann-Whitney U-test).
(N) Lapatinib decreases neurosphere diameters in Nf2-deficient SC
NPCs (p,0.001; two-way ANOVA with Bonferroni post-test). (O)
Nf2-deficient SC NPCs exhibit a 2.6-fold increase in Rac1 activity
compared to WT SC NPCs (p= 0.0109); two-tailed Mann-
Whitney U-test). (P) b-catenin (regulator of cell-cell adhesion)
expression is not changed in Nf22/2 NPCs relative to their WT
counterparts (p = 0.9600; two-tailed Mann-Whitney U-test). Val-
ues denote the mean 6 SEM. (*) p,0.05; (**) p,0.001; (***) p,
0.0001.
(TIF)
Table S1 Plasmids. Murine stem cell virus (MSCV) and
lentiviral plasmids used.
(DOCX)
Table S2 Antibodies. Antibodies used, source and dilutions.
Immunocytochemistry (ICC), Immunohistochemistry (IHC) and
Western Blot (WB), Ms: Mouse antibody; Rb: Rabbit antibody,
Cl. = cleaved, p- = phospho-.
(DOCX)
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